GleamWall
中文EN

HUMA Humacyte, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1818382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY52.5%
TTM net income YoY-156.3%
TTM EPS YoY-66.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-475.1%
Operating margin-4,602.9%
Net margin-3,955.1%
FCF margin-3,697.0%
EBITDA margin-4,381.8%

Returns

ROE-1,423.6%
ROA-87.3%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets85.6%
Debt / equity2.04x
Current ratio3.34x
Interest coverage-10.97x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue13.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.04M$0
Cost of revenue$9.70M$0
Gross profit-$7.66M$0
R&D expense$69.30M$88.60M
SG&A expense$31.17M$25.80M
Operating income-$108.14M-$114.40M
Interest expense$11.25M$9.28M
Pretax income-$40.83M—
Income tax$0$0
Net income-$40.83M-$148.70M
EBITDA-$102.81M-$109.29M
EPS (basic)-0.26-1.26
EPS (diluted)-0.26-1.26
Weighted avg. shares (diluted)158.16M118.48M
Balance sheet
Cash & equivalents$50.50M$95.29M
Receivables$441,000$0
Inventory$13.59M$0
Current assets$67.80M$47.86M
PP&E, net$18.54M$23.06M
Total assets$116.37M$137.87M
Current liabilities$18.37M$19.95M
Long-term debt$35.44M$0
Total debt$35.44M$0
Total liabilities$113.26M$190.54M
Shareholders' equity$3.11M-$52.67M
Net debt-$15.05M-$95.29M
Shares outstanding193.00M130.03M
Cash flow statement
Operating cash flow-$105.04M-$98.12M
Capital expenditure$884,000$1.57M
Free cash flow-$105.93M-$99.69M
Investing cash flow-$884,000-$1.57M
Financing cash flow$61.49M$114.18M
Depreciation & amortization$5.33M$5.10M
Stock-based compensation$9.75M$6.14M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.